Top news story of the day:
Arnatar Therapeutics closes round of Seed financing to advance antisense technology drug development
Arnita Therapeutics announced the completion of a round of Seed financing worth nearly 100 million RMB led by Apricot Capital. The company will use the funds to develop its R&D platform based on antisense nucleic acid bidirectional regulation technology and to advance multiple innovative drug pipelines.
Founded in 2022, Arnatar has developed two technology platforms to expand the range of treatable diseases. One is a highly efficient siRNA technology platform. The other is an ASO technology platform for bidirectional regulation of protein expression.
“Arnatar's name has two meanings. First, it means advanced RNA targeting, a reference to our core technology. The second means innovation, confidence and vitality, which drive our company.”Arnatar founder, Dr. Yanfeng Wang said, “We are actively promoting the development of multiple pipeline drugs and intend to advance the drug’s IND enabling as soon as possible.”
In other news:
Viewgene closed Series Pre-A financing worth several tens of millions of RMB to advance its next-generation inducible gene therapy platform technology.
Ailomics Therapeutics announced the completion of a round of Angel financing worth several tens of millions of RMB to develop the company's core technology platform and R&D pipelines.
Ascletis BioScience signed an addendum agreement with Roche on September 16 and will terminate promotion services from Pegasys effective December 31, 2022.
On September 17, China’s National Healthcare Security Administration (NHSA) released an updated Medicare reimbursement list. 343 drugs have passed the preliminary review process, including 198 off-catalog drugs and 145 on-catalog drugs.
By Danni Yin